New proton combo aims to improve esophageal cancer treatment

NCT ID NCT01684904

Recruiting now Disease control Sponsor: Loma Linda University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing a combination of proton radiation and chemotherapy (carboplatin and paclitaxel) before surgery for patients with resectable esophageal or esophagogastric junction cancer. The goal is to see if this approach is safe, tolerable, and effective at improving overall survival. The study enrolls 38 participants with specific stages of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: proton radiation combined with carboplatin and paclitaxel chemotherapy
What this could lead to: If successful, this could offer a more effective and less toxic treatment option for esophageal cancer patients, potentially improving survival rates.
What could go wrong: This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. The treatment still carries risks of side effects from both chemotherapy and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC JUNCTION CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGUS CANCER

Contacts and locations

Locations

Loma Linda University Medical Center
RECRUITING

Loma Linda, California, 92354, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.